Torrent Pharma Launches Semaglutide Formulations in India
Mumbai, March 21, 2026 – Torrent Pharmaceuticals Limited announced the launch of its Semaglutide brands, Sembolic and Semalix, in India. The company is introducing both oral and injectable formulations, expanding its presence in the treatment of metabolic disorders like type-2 diabetes and obesity. Torrent Pharma is the first Indian company to launch generic oral semaglutide. The injectable formulation is available starting at Rs. 3,999 per month.“Metabolic disorders represent one of the most significant healthcare challenges in India,” said Amal Kelshikar, CEO - India Business, Torrent Pharma. “Our entry into the GLP-1 therapy segment reflects Torrent's commitment to expanding treatment options at affordable prices.”
About GLP-1 Drugs
GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medications used to manage type 2 diabetes and obesity. They function by increasing insulin release, reducing glucagon levels, and regulating appetite. These drugs have demonstrated effectiveness in lowering hemoglobin A1c (HbA1c), promoting weight loss, and reducing the risk of cardiovascular events.About Torrent Pharmaceuticals Limited
Torrent Pharma, with annual revenues exceeding Rs 11,500 crores, is the flagship company of the Torrent Group, which reports group revenues of approximately Rs 45,000 crores. Following the acquisition of JB Pharma, Torrent Pharma ranks 5th in the Indian Pharmaceuticals Market and among the top 5 companies in the cardiovascular, gastrointestinal, central nervous system, pain management, and cosmo-dermatology therapeutic segments. The company operates in over 50 countries and is the leading Indian pharmaceutical company in Brazil and Germany. Torrent Pharma has 8 manufacturing facilities, 5 of which are USFDA-approved. The company employs approximately 750 scientists and has invested significantly in research and development capabilities.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.